3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
4 citations
,
June 2015 in “Journal of Genetics/Journal of genetics” Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
November 2025 in “Preprints.org” Phenytoin and spironolactone help prevent hair loss from chemotherapy by reducing stress and inflammation.
5 citations
,
January 1991 in “Drugs of The Future”
16 citations
,
December 2012 in “Bioinformation” Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
September 2003 in “Reactions Weekly” November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
3 citations
,
October 1993 in “Endocrinology”
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
May 2004 in “International Journal of Cosmetic Science” Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.
10 citations
,
May 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.